The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo

Chemico-Biological Interactions

Volumn 159, Issue 2, 2006, Pages 90-103

  Majumder, S ^a   Dutta, P ^a   Mookerjee, A ^a   Choudhuri, S K ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

Author keywords

Copper N (2 hydroxy acetophenone) glycinate; Doxorubicin; Drug resistance; Glutathione; Resistance modifying agent

Indexed keywords

ACETOPHENONE DERIVATIVE; COPPER COMPLEX; COPPER N (2 HYDROXY ACETOPHENONE) GLYCINATE; DEXTRO LEVO BUTHIONINE SULFOXAMINE; DOXORUBICIN; ETACRYNIC ACID; GLUTATHIONE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; SULFUR DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; EHRLICH ASCITES TUMOR; ENZYME ACTIVITY; FLOW CYTOMETRY; IMMUNOBLOTTING; IN VIVO STUDY; LIFESPAN; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; TUMOR PROMOTION; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, EHRLICH TUMOR; CASPASE 3; CASPASES; COPPER; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GLUTATHIONE; GLUTATHIONE TRANSFERASE; MALE; MICE;

ANIMALIA;

EID: 29944442370     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2005.10.044     Document Type: Article

References (40)

1. T. Litman, T.E. Druley, W.D. Stein, and S.E. Bates MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance Cell. Mol. Life Sci. 58 2001 931 959
2. S.P.C. Cole, G. Bhardwaj, J.I.I. Gerlac, J.E. Mackie, C.E. Grant, K.C. Almquist, A.J. Stewart, E.U. Kurz, A.M.V. Dincun, and R.G. Deeley Overexpression of a transport gene in a multidrug-resistant human lung cancer line Science (Washington, DC). 258 1992 1650 1654
3. P. Borst, R. Evers, M. Kool, and J. Wijnholds The multidrug resistance protein family Biochim. Biophy. Acta 1461 1999 347 357
4. T.K. Bera, C. Iavarone, V. Kumar, S. Lee, B. Lee, and I. Pastan MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer Proc. Natl. Acad. Sci. 99 2002 6997 7002
5. K. Nooter, A.M. Westerman, M.J. Flens, G.J. Zaman, R.J. Scheper, K.E. van Wingerden, H. Burger, R. Oostrum, T. Boersma, and P. Sonneveld Expression of the multidrug resistance-associated protein (MRP) gene in human cancers Clin. Cancer Res. 1 1995 1301 1310
6. B. Vergier, L. Cany, F. Bonnet, J. Robert, A. de Mascarel, and J.M. Coindre Expression of MDR1/P glycoprotein in human sarcomas Br. J. Cancer 68 1993 1221 1226
7. Y. Cui, J.K. Buchholz, I.I. Spring, I. Leier, and D. Keppler Drug resistance and ATP dependent conjugate transport, mediated by the apical multi drug resistance protein, MRP2, permanently expressed in human and canine cells Mol. Pharmocol. 55 1999 929 937
8. A.A. Stavrovstaya Cellular mechanisms of multidrug resistance of tumor cells Biochemistry (Moscow) 65 1 2000 95 106
9. M.M. Gottesman, and I. Pastan Biochemistry of multidrug resistance mediated by the multidrug transporter Ann. Rev. Biochem. 62 1993 385 427
10. E. Bakos, R. Evers, E. Sinko, A. Varadi, P. Borst, and B. Sarkadi Interaction of the human multidrug resistance proteins MRP1 and MRP2 with organic anions Mol. Pharmacol. 57 2000 760 768
11. J.P. van Brussel, M.A. Oomen, P.J. Vossebeld, E.A. Wiemer, P. Sonneveld, and G.H. Mickisch Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine BJU Int. 93 2004 1333 1338
12. H. Takemura, Y. Urasaki, A. Yoshida, T. Fukushima, and T. Ueda Simultaneous treatment with 1-beta-d-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells Cancer Res. 61 2001 172 177
13. S. Gallego, A. Llort, A. Parareda, and J.S. De toledo Expression of multidrug resistance-1 and multidrug resistance associated protein genes in pediatric rhabdomyosarcoma Oncol. Rep. 11 2004 179 183
14. Y. Chuman, Z.S. Chen, K. Seto, T. Sumizawa, T. Furukawa, A. Tani, M. Haraguchi, K. Niwa, K. Yamada, T. Aikou, and S. Akiyama Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK Cancer Lett. 129 1 1998 69 76
15. R.A. Davey, T.J. Longhurst, M.W. Davey, L. Belov, R.M. Harvie, D. Hancox, and H. Wheeler Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line Leuk. Res. 19 4 1995 275 282
16. T. Efferth, and M. Volm Reversal of doxorubicin-resistance in sarcoma 180 tumor cells by inhibition of different resistance mechanisms Cancer Lett. 16 1993 197 202
17. P.J. Dierickx Long-term buthionine-sulfoximine-mediated toxicity in cultured hepatoma cell lines Res. Commun. Chem. Pathol. Pharmacol. 67 1990 423 426
18. S. Majumder, G.S. Panda, and S.K. Choudhuri Synthesis, characterization and biological properties of a novel copper complex Eur. J. Med. Chem. 38 2003 893 898
19. S.K. Choudhuri, P. Dutta, S. Majumder, and A. Mookerjee Development of a novel resistance modifying agent to overcome multidrug resistance in cancer Invited Oral Presentation at World Conference on Magic Bullets, Celebrating Paul Ehrlich's 150th Birthday Nurenberg, Germany, 9-11 September 2004 A-26
20. T.S. Basu baul, S. Dutta, E. Rivarola, M. Scopelliti, and S.K. Choudhuri Synthesis, characterization of diorganotin(IV) complexes of N-(2- hydroxyarylidene) aminoacetic acid and antitumor screening in vivo in Ehrlich ascites carcinoma cells Appl. Organometal. Chem. 15 2001 947 953
21. D. Dakternieks, T.S. Basu Baul, S. Dutta, and E.R.T. Tiekink Synthesis, characterization and X-ray structures of diphenyltin(IV) N-(2- hydroxyacetophenone)glycinate, its 1:1 adduct with triphenyltin(IV) chloride and related systems Organometallics 17 1998 3058 3062
22. E. Friche, M.K. Danks, and W.T. Beck Characterization of tumor cell resistance to 4-deoxy-4-iododoxorubicin developed in Ehrlich Ascites cells in vitro Cancer Res. 52 1992 5701 5706
23. S.K. Choudhuri, and A. Chatterjee Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(N-phenyl) hydroxamic acid in vitro Anti-Cancer Drugs 9 1998 825 832
24. S. Majumder, P. Dutta, S.K. Choudhuri, The role of copper in development of drug resistance in murine carcinoma, Med. Chem. 1, in press.
25. T. Tsuoro, H. Iisida, S. Tsukagoshi, and Y. Sakurai Overcoming vincristine resistance in P-388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine, vinblastin by verapamil Cancer Res. 41 1981 1967 1972
26. C. Tolis, G.J. Peters, G.C. Ferreira, H.M. Pinedo, and G. Giaccone Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines Eur. J. Cancer 35 1999 796 807
27. J.F.R. Kerr, C.M. Winterford, and V. Harmon Apoptosis its significance in cancer and cancer therapy Cancer 73 1994 2013 2016
28. J. Sedlack, and R.N. Lindsay Estimation of total protein-bound and non protein sulphohydral groups in tissues with Ellmans reagent Anal. Biochem. 25 1968 192 205
29. O.H. Lowry, N.J. Rosenberg, A.L. Farr, and R.J. Randal Protein measurement with folin phenol reagent J. Biol. Chem. 196 1951 265 271
30. W.H. Habig, M.J. Pabst, and W.B. Jakoby Glutathione S-transferase. The first enzymatic step in marcapturic acid formation J. Biol. Chem. 249 1974 7130 7139
31. C. Herold, M. Ocker, M. Ganslmayer, H. Geraner, E.G. Hahn, and D. Schuppan Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells Brit. J. Cancer 86 2002 443 448
32. A. Arora, K. Seth, and Y. Shukla Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver Carcinogenesis 25 2004 941 949
33. Y. Gong, M. Durvuri, and J. Krise Separate roles for the golgi apparatus and lysosomes in the sequestration of drugs in the multidrug-resistant human leukemic cell line HL-60 J. Biol. Chem. 278 50 2003 50234 50239
34. P. Borst, R. Evers, M. Kool, and J. Wijnlolds A Family of drug transporters: the multidrug resistance associated proteins J. Natl. Cancer Inst. 92 16 2000 1295 1302
35. M. Marszalek, M. Bartosz, and G. Bartosz There is no evidence for the existence of complex formation between doxorubicin and glutathione Cell. Mol. Biol. Lett. 8 2003 311 315
36. J. Lie, H. Chen, D.S. Miller, J.E. Saavedra, L.K. Keefer, D.R. Jhonson, D.C. Klaassen, and M.P. Waalkes Overexpression of glutathione S-transferase and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic Mol. Pharmacol. 60 2001 302 309
37. U. Vanhoefer, S. Cao, H. Minderman, K. Toth, B.S. Skenderis, M.L. Slovak, and Y.M. Rustum d,l-Buthionine-(S,R)-sulfoxamine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein expressing tumors Clin. Cancer Res. 2 1996 1961 1968
38. C.H. Versantvoort, H.J. Broxterman, T. Bagrij, R.J. Scheper, and P.R. Twentyman Regulation of drug transport by GSH in multidrug resistant human lung tumour cell lines overexpressing multidrug resistanceassociated protein Br. J. Cancer 72 1995 82 89
39. D.W. Loe, R.G. Deeley, and S.P. Cole Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione Cancer Res. 58 1998 5130 5136
40. Y. Sadzuka, T. Sugiyama, and T. Sonobe Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance Toxicol. Lett. 114 2000 155 162